似たピン
DePuy Synthes、Johnson & Johnsonから分離
推定確度 71%281 日後2026年6月28日締め四半期のJ&Jの10-Qは、2025年10月14日の「当初発表から18〜24か月以内の完了」(2027年4月半ば〜10月半ば)を目標としており、Joseph Wolk CFOは7月に、J&Jは「2027年半ばの分離に向け順調だ」と述べた(Bloomberg)。「2027年半ば」は年央、すなわち2027年7月1日と解釈され、この期間内に収まる。[1]Johnson & Johnsonの整形外科事業は、DePuy Synthesとしてグループから分離される見通し。非課税スピンオフか売却かの選択肢があり、Apolloが約200億ドルで交渉中。J&Jは2027年半ばの分離に向け順調だとしている。0.79J&J Announces Plan to Spin Off DePuy Synthes
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
確定確度 90%344 日前The release is datelined "NEW BRUNSWICK, NJ, October 14, 2025 - Johnson & Johnson ... today announced the Company's intent to separate its Orthopaedics business"; it states no time of day (CNBC's[3] report was up at 6:29 a.m. EDT and J&J's X post at 6:40 a.m. EDT), so the pin is the all-day 14 October.Johnson & Johnson said it would separate its roughly $9.2 billion-a-year orthopaedics business into a standalone company called DePuy Synthes within 18 to 24 months, and named former Smith & Nephew chief Namal Nawana to run it.0.73J&J Completes Its $1 Billion Acquisition of Firefly Bio
確定確度 87%56 日前"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.$1B0.63J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
確定確度 82%58 日前J&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.$5.5B0.61Abbott Agrees to Buy Exact Sciences for $21 Billion
確定確度 86%307 日前The release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".[1]Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.$21B0.60- $843M0.59
Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
確定確度 87%120 日前Lilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".[1]Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.$3.8B0.58Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
確定確度 88%23 日前The release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".[1]Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.$2.9B0.58Inside Tesla's $5 Billion Gigafactory - Visual Capitalist
The $5 Billion Tesla Gigfactory will set a new precedent for economies of scale in battery production, creating demand for graphite, cobalt, and lithium. The name gigafactory comes from the plant's planned annual battery production capacity of 35 gigawatt-hours, which Tesla said on Wednesday it would achieve by 2018.$5B0.58- 0.58
Babcock & Wilcox Gets Go-Ahead on $2.4B Base Electron Power Plant
確定確度 87%203 日前Stated as done, per babcock.com[1]: "(AKRON, Ohio - March 4, 2026) - Babcock & Wilcox ... announced today that it has received full notice to proceed on a $2.4 billion design-build agreement"; the Business Wire copy on Yahoo Finance is timestamped 11:30 UTC.Babcock & Wilcox received full notice to proceed on a $2.4 billion design-build contract with Base Electron, an Applied Digital-backed power producer, for 1.2 GW of gas-fired boiler and steam turbine capacity to supply Applied Digital AI Factory campuses.$2.4B0.58Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
確定確度 87%176 日前The joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".[1]Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.$7.8B0.58
